HOME >> BIOLOGY >> NEWS
Honeybee gene find ends 150-year search

The genetic signal that makes a honeybee male or female has been identified by researchers in Germany, the U.S. and Norway. The finding, published in the August 22 issue of the journal Cell, shows how male bees can have no father, a scientific puzzle going back over 150 years and the explanation for why bees, ants and wasps often form colonial societies. It could also make it easier to breed honeybees.

The researchers found that female bees have two different versions of a gene called csd, one from each parent, that form an active protein that triggers female development. Unfertilized eggs, which have only one copy of csd from the mother, default to being males.

In 1845, a Polish parish priest called Johann Dzierzon proposed that male bees have no fathers: They develop from unfertilized eggs, while females grow from fertilized eggs. Later work showed that Dzierzon was right. Male bees have half as many genes (haploid) as females, which get a set of genes from each parent (diploid). About one-fifth of animal species including all ants, bees and wasps use a similar haplodiploid system of sex determination, but the actual genes and mechanisms involved are not well understood.

Martin Beye and Martin Hasselmann from the Martin Luther University of Halle/Wittenberg, Germany, and Robert Page and Kim Fondrk at the University of California, Davis, isolated a honeybee gene called complementary sex determiner, or csd. Csd exists in 19 alternative versions, or alleles, Page said. Female bees have two copies of csd which are always different alleles. Males have only one copy.

The researchers worked out the DNA sequence of four csd alleles and found that they were highly variable. But the same alleles were found in both males and females, showing that there are no alleles for "maleness" or "femaleness."

Studies on developing eggs showed that in both males and females, the csd gene becomes active about 12 hours after eggs are laid and remain
'"/>

Contact: Andy Fell
ahfell@ucdavis.edu
530-752-4533
University of California - Davis
21-Aug-2003


Page: 1 2 3

Related biology news :

1. USDA establishes Honeybee Genetics and IPM Center
2. Summer Science: Where Have All The Honeybees Gone? UD Bee Guy Asks Why--From America To The Amazon
3. Careful Honeybee Breeding Combats Tracheal Mite Pests
4. Honeybees In The Wild Nearly Gone In North America
5. 150-year global ice record reveals major warming trend
6. Leader in cancer treatment and prevention research honored
7. Landmark agreement between Samoa and UC Berkeley could help search for AIDS cure
8. Researchers determine genetic cause of Timothy syndrome
9. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative
10. Scientists to prototype cyberinfrastructure for research and education access to ocean observatories
11. Belgian researchers explore revolutionary approach to angiogenesis

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Honeybee gene find ends year search

(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
(Date:2/28/2015)... 2015 Increasing its efforts to resolve the ... first three episodes of The GMO TRUTH podcast on both ... as it continues its mission to discover the truth and ... phase, to “uncover the truth about the GMOs in our ... GMO Truth Podcast is an expansion of the documentary/investigative film-making ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
Cached News: